Elvitegravir
From Proteopedia
(Difference between revisions)
| (6 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | < | + | <StructureSection load='' size='340' side='right' caption='The Investigational Drug, Elvitegravir, ([[3l2u]])' scene='Elvitegravir/Elvitegravir/1'> |
===Better Known as: N/A=== | ===Better Known as: N/A=== | ||
* Marketed By: Gilead Sciences | * Marketed By: Gilead Sciences | ||
| Line 7: | Line 7: | ||
* Projected 2013 Sales: $460 Million | * Projected 2013 Sales: $460 Million | ||
* Importance: It is expected to be the next effective HIV treatment to come to market. Expected to be the second [[Retroviral Integrase]] inhibitor approved. Currently in phase III clinical trials. Results from phase II trials indicate that the once-daily treatment was more effective than current [[HIV Protease]] inhibitor combinations.<ref>PMID:17977962</ref> | * Importance: It is expected to be the next effective HIV treatment to come to market. Expected to be the second [[Retroviral Integrase]] inhibitor approved. Currently in phase III clinical trials. Results from phase II trials indicate that the once-daily treatment was more effective than current [[HIV Protease]] inhibitor combinations.<ref>PMID:17977962</ref> | ||
| - | * | + | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders. |
===Mechanism of Action=== | ===Mechanism of Action=== | ||
| - | [[Retroviral Integrase]] is produced by the HIV retrovirus, enabling [[HIV]] to integrate its genetic material into the [[DNA]] of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit.<ref>PMID:17107277</ref> HIV retroviral integrase forms "intasomes" when it <scene name='Elvitegravir/Full/1'>complexes with viral DNA</scene>. The integrase domains interact extensively with the viral DNA, <scene name='Elvitegravir/Tight/1'>binding the nucleotide chains</scene> precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. Elvitegravir binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. <scene name='Elvitegravir/Tightasdf/2'>Elvitegravir binds</scene> to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.<ref>doi: 10.1038/nature08784</ref> | + | [[Retroviral Integrase]] is produced by the HIV retrovirus, enabling [[HIV]] to integrate its genetic material into the [[DNA]] of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit.<ref>PMID:17107277</ref> HIV retroviral integrase forms "intasomes" when it <scene name='Elvitegravir/Full/1'>complexes with viral DNA</scene>. The integrase domains interact extensively with the viral DNA, <scene name='Elvitegravir/Tight/1'>binding the nucleotide chains</scene> precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. Elvitegravir binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. <scene name='Elvitegravir/Tightasdf/2'>Elvitegravir binds</scene> to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.<ref>doi: 10.1038/nature08784</ref><ref>PMID:21030679</ref> |
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
| - | + | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="50%"> | |
| - | + | <tr> | |
| - | + | <td style="width:auto; vertical-align:top;border-width:0px; border-style:inset"> | |
| - | + | <div style="height:100%; width: 100%"> | |
| - | + | {{:Retroviral Integrase Inhibitor Pharmacokinetics}} | |
| - | + | </div> | |
| - | + | </td> | |
| - | + | </tr> | |
| - | + | </table> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| + | </StructureSection> | ||
===References=== | ===References=== | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
__NOTOC__ | __NOTOC__ | ||
Current revision
| |||||||||||
References
- ↑ Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. Epub 2007 Oct 31. PMID:17977962 doi:10.1128/JVI.01534-07
- ↑ Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507-22. PMID:17107277 doi:10.1517/13543784.15.12.1507
- ↑ Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010 Mar 11;464(7286):232-6. Epub 2010 Jan 31. PMID:20118915 doi:10.1038/nature08784
- ↑ Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A. 2010 Oct 28. PMID:21030679 doi:10.1073/pnas.1010246107
